2021
DOI: 10.3390/jcm10071415
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Tranexamic acid (TXA) protects against endothelial glycocalyx injury in vitro. We aimed to evaluate whether TXA could protect against endothelial glycocalyx degradation in patients undergoing posterior lumbar fusion surgery. Patients aged 30–80 years were enrolled. The TXA group was administered a loading dose of 10 mg/kg, followed by a 1 mg/kg/h infusion. Serum syndecan-1 and heparan sulfate concentrations, which are biomarkers of glycocalyx degradation, were measured at preoperative baseline (T0), immediatel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…Tranexamic acid is a synthetic lysine derivative that inhibits plasminogen activation and its binding to fibrin, thereby inhibiting fibrinolysis (104). A recent study showed pre-and peri-operative administration of tranexamic acid in patients undergoing posterior lumbar fusion surgery significantly inhibited the 2 h postoperative increase in plasma syndecan-1 compared to untreated patients (105). A study of patients with moderate to severe traumatic brain injury showed a modest but significant decrease in plasma syndean-1 when tranexamic acid was administered within 2 h postinjury (106).…”
Section: Protease Inhibitorsmentioning
confidence: 99%
“…Tranexamic acid is a synthetic lysine derivative that inhibits plasminogen activation and its binding to fibrin, thereby inhibiting fibrinolysis (104). A recent study showed pre-and peri-operative administration of tranexamic acid in patients undergoing posterior lumbar fusion surgery significantly inhibited the 2 h postoperative increase in plasma syndecan-1 compared to untreated patients (105). A study of patients with moderate to severe traumatic brain injury showed a modest but significant decrease in plasma syndean-1 when tranexamic acid was administered within 2 h postinjury (106).…”
Section: Protease Inhibitorsmentioning
confidence: 99%